Reasons for Failure and Relapse and Mechanism...

In this episode, Dr Alexandra Martínez Roca and Dr Beatriz Merchán Muñoz discuss how their team at Hospital Clínic de Barcelona has developed a fully outpatient programme for CAR T-cell therapy. They explain the evolution of their at-home programme, from outpatient transplantatio ...  Show more

Artificial intelligence is opening new possibilities in the design of next-generation immunotherapies. In this episode of EHA Unplugged, Dr Andrea Schmidts discusses how AI-driven approaches are reshaping the development of chimeric antigen receptor (CAR) T-cell therapies, partic ...  Show more

In Part 1 of this pair of episodes, Drs. Rita Dib and Joseph Sassine provide a background of CAR-T cell therapy (chimeric antigen receptor T cells) and steer you through the complications that might contribute to fever early after CAR-T.Episodes | Consult Notes | Subscribe | Twit ...  Show more

In Part 2 of this pair of episodes, Drs. Rita Dib and Joseph Sassine zoom through the late infectious complications of CAR-T cell therapy.Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.com 

This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we h ...

How can you optimize the treatment pathway for relapsed or refractory chronic lymphocytic leukemia (CLL)? Join the experts as they delve into the latest updates from EHA 2024.
  
Credit available for this activity expires: 07/31/25
Earn Credit / Learning Obje ...